Shares of Gland Pharma Ltd gained 1.62%, reaching ₹1,880.00, following the National Stock Exchange of India Ltd (NSE)’s announcement to include the stock in its futures and options (F&O) segment. This development is part of NSE’s move to expand the F&O contracts list, effective January 31, 2025.
Key Highlights:
- Inclusion Announcement: Gland Pharma is among six new securities approved for F&O trading by NSE, in alignment with SEBI’s August 30, 2024, circular.
- Market Reaction: The stock opened at ₹1,865.05, touched a high of ₹1,912.90, and a low of ₹1,865.05 during the day.
- Market Cap: Gland Pharma’s market capitalization stands at ₹309.73 billion.
- NSE’s F&O Expansion: The inclusion follows the regulator’s guidelines, alongside other stocks like NBCC, Castrol India, and Torrent Power.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
